Results 121 to 130 of about 42,175 (206)

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder. [PDF]

J Prim Care Community Health
Meilinger A, Campbell MA, Reynolds HM, Chavez AS.   +3 more
europepmc   +1 more source

Ülseratif kolitli hastalarda `glucagon like peptide-1` ve `glucagon like peptide-2` düzeyleri

, 2020
Giriş-Amaç: Ülseratif kolit hastalığı barsağın kronik inflamatuvar bir hastalığıdır. ?Glucagon like peptide-1? barsak enteroendokrin L hücrelerinden salgılanan ve kan şekerinin düzenlenmesinde görevli bir peptiddir. ?Glucagon like peptide-2? de barsak enteroendokrin L hücrelerinden salgılanır ve barsak mukoza bütünlüğünün korunmasında görevlidir ...
openaire   +1 more source

Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. [PDF]

Obstet Gynecol
Lessard C, Cary C, In A, Steinle J, Lin BY, Kablinger AS, Grucza RA, Bello JK, Galati BM, Kimmel M, Bruno AM, Kelly JC, Xu KY.   +12 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. [PDF]

PLoS Med
Chao AM, Gilden A, Wadden TA.
europepmc   +1 more source

Xenin-Derived Peptides: Multifaceted Regulators and Therapeutic Innovations in Metabolic Diseases. [PDF]

Drug Des Devel Ther
Gong B, Liu X, Hu G, Li T, Chen F, Sun X, Sun L, Xu Y.   +7 more
europepmc   +1 more source

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. [PDF]

J Manag Care Spec Pharm
Marshall LZ, Gleason PP, Friedlander N, Farley J, Urick BY.   +4 more
europepmc   +1 more source

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. [PDF]

Pharmacol Res
Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN.   +5 more
europepmc   +1 more source

Neuropeptides and the Autonomic Nervous System in Prader-Willi Syndrome. [PDF]

Int J Mol Sci
Höybye C, Petersson M.
europepmc   +1 more source

Peptides from Animal Venoms: A Promising Frontier in Diabetes Therapy via Multi-Target Mechanisms. [PDF]

Pharmaceuticals (Basel)
de Almeida JOCS, Comerma-Steffensen SG, de Souza de Almeida Leite JR, Simonsen U, Arcanjo DDR.   +4 more
europepmc   +1 more source

Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease. [PDF]

Front Bioinform
Wong A, Guduri S, Chen T, Patel K.
europepmc   +1 more source